Title: Clinical comparison between two formulations of metoprolol in the treatment of mild hypertension
Abstract: Objective To compare the clinical curative effect and safety between different formulation of metoprolol. Methods Sixty-four cases of primary hypertension patients were randomly divided into two groups, conventional group (n = 32) and sustained-release tablets group (n = 32). Patients in conventional group received oral administration of metoprolol tartrate tablets 12.5 mg twice a day, which can be increased to 25 mg twice a day, and the patients in sustained-release tablets group who received metoprolol succinate sustained-release tablets 23.75 mg daily, or raising dose 47.5 mg daily for same indications. Consulting room blood pressure, 24 hour ambulatory blood pressure monitoring (ABPM), 24 hours of dynamic electrocardiogram, function of liver and kidney, level of plasma glucose and lipid, and adverse reaction caused by metoprolol were recorded before received therapeutics or after 6 weeks. Results There was no significant difference in the rate of achieving the goal of treatment between the two groups (P 0.05), in spite of the target BP goal rate were high (78.1% vs 87.5%) after 6 weeks. In two groups, ABPM showed that systolic blood pressure (SBP) and diastolic blood pressure (DBP) were significantly lower than that before treatment (P 0.05), but there was no significant difference between two groups (P 0.05), while morning blood pressure peak incidence decreased significantly (P 0.05) in release group. There was no significant difference in two groups about the average heart rate. SDNN, RMSSD, PNN50 of sustained-release tablets group significantly increased compared with conventional group (P 0.05). The liver and kidney function and blood lipids, blood glucose of two groups before and after experiment had no significant difference (P 0.05), and had no obvious adverse drug reactions. Conclusion Metoprolol monotherapy has a high antihypertensive efficacy for mild hypertension, and metoprolol sustained-release form can significantly reduce the peak morning blood pressure and increase heart rate variability comparing with metoprolol tartrate from.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot